FDAsafety guidance66% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (copd) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Respiratory · COPD
- Sub-indication
- COPD
Related signal: FDA Approves Supplemental Application for Breztri Aerosphere